Exact Sciences recently announced its second quarter numbers, which included revenue of $57.6 million and 135,000 completed Cologuard tests, an increase of 172 percent and 149 percent, respectively.

“As patient and physician demand for Cologuard continues to grow, momentum is increasing toward Cologuard becoming part of the standard of care in colon cancer screening,” Exact Sciences Chairman and CEO Kevin Conroy said in a statement. “We will continue investing in the long-term and sustainable growth of Cologuard to ensure the millions of people who need to be screened for colon cancer have access to our non-invasive test.”

According to a release, Exact Sciences anticipates 2017 revenues between $230 million and $240 million with 550,000 completed Cologuard tests.

To date, roughly 235 million Americans are members of health plans that cover Cologuard.